PRINCETON, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) is scheduled to announce its 2007 fourth quarter and
year-end results on Tuesday, February 26, 2008 by press release after the
financial markets close.
Following the release, Medarex's management will host a conference call
and live webcast at 4:30 p.m. Eastern Time. To access the call live, please
dial 1-866-510-0710 (U.S./Canada) or 1-617-597-5378 (international) and
enter passcode number 15176024. The webcast can be accessed through the
Investor Relations section of Medarex's website at http://www.medarex.com and will
be archived for 14 days following the webcast.
A telephonic replay of the conference call will be available until
midnight Eastern Time, March 4, 2008. Access numbers for this replay are
1-888-286-8010 (U.S./Canada) or 1-617-801-6888 (international); passcode
number 75836084.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. Over thirty of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase 3 clinical trials. Medarex is committed to building
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its website at http://www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.
 back to top
Related links:
http://www.medarex.com
http://www.prnewswire.com/comp/108265.html /
CONTACT:
Christian S. Schade, Senior VP and CFO,
+1-609-430-2880, Laura S. Choi, Investor Relations,
+1-609-430-2880, ext. 2216, or Jean Mantuano, Corporate
Communications (media), +1-609-430-2880, ext. 2221, all of
Medarex, Inc.
|
